Cargando…
SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
INTRODUCTION Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition is an effective strategy for lowering plasma LDL-cholesterol and enhancing the LDL-cholesterol lowering ability of statins. PCSK9, a serine protease that binds to the LDL receptor promoting its degradation, is an important...
Autor principal: | Iwabuchi, Masayasu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209628/ http://dx.doi.org/10.1210/jendso/bvaa046.477 |
Ejemplares similares
-
SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020) -
SAT-576 Lyme Disease Associated Thyroiditis
por: Deol, Navreet, et al.
Publicado: (2019) -
SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020) -
PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021) -
FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)